|Bid||2.1000 x 800|
|Ask||4.9900 x 1200|
|Day's Range||3.2500 - 3.4000|
|52 Week Range||3.2100 - 11.9000|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 15, 2019 - Feb 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.50|
RESTORE Consortium, of which Pluristem is a leading member, is competing for up to a €1 billion award by the European CommissionWinner announcement is expected in May 2020.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
PLX cell therapy was granted an Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of ARS and incomplete hematopoietic recovery following hematopoietic cell transplantation (HCT). An overview of HCT was provided by Dr. Jacob M. Rowe, MD, Chief of the Department of Hematology and The Ann and Pinky Sohn Chair in Hemato-Oncology at the Shaare Zedek Medical Center in Jerusalem and Emeritus Professor at the Technion, Israel Institute of Technology in Haifa, a member in the company’s ongoing hematology program steering committee.
Pluristem Therapeutics (PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced additional information relating to its live Key Opinion Leader (KOL) call regarding its hematological programs on September 16, 2019. The call will feature presentations by Jacob M. Rowe, MD and Bert. W. Maidment, Ph.D, and will include discussions regarding the findings from Pluristem’s ongoing clinical study in hematological deficiencies, as well as opportunities and future product development.
Long term investing works well, but it doesn't always work for each individual stock. We don't wish catastrophic...
Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the company will host a live Key Opinion Leader (KOL) call on its hematological programs on September 16, 2019. The call will feature presentations by KOLs and Pluristem’s management who will explain and discuss the status of the company’s radiation programs with the U.S government, including an overview of recent Department of Defense (DoD) radiation data, potential markets and expected milestones. In addition, KOLs will discuss findings from Pluristem’s ongoing clinical study in hematological deficiencies, as well as opportunities and future product development.
Israel's Pluristem Therapeutics Inc reported on Wednesday positive results from a series of studies in animals of its placenta-based stem cell therapy to treat acute radiation syndrome (ARS). The studies were conducted by the U.S. Department of Defense’s Armed Forces Radiobiology Research Institute. The tests, conducted via the Food and Drug Administration's "animal rule pathway" as ARS cannot be tested in humans, were designed to evaluate Pluristem's PLX-R18 as a preventative treatment for ARS before radiation exposure.
PLX-R18 demonstrated significant increase in survival rates and recovery of the three blood lineagesData is jointly presented at the 2019 Radiation Injury Treatment Network.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 24) Acasti Pharma Inc (NASDAQ: ACST ) Cardiovascular Systems ...
Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today issued an update to its shareholders from its Chief Executive Officer, Yaky Yanay, commenting on the Company’s proposed reverse stock split. Today we announced a 1-for-10 reverse split of the company’s authorized, as well as issued and outstanding shares of common stock and authorized preferred stock.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 23) Akero Therapeutics Inc (NASDAQ: AKRO ) Mirum Pharmaceuticals ...
The reverse split will be effective as of market open on July 25, 2019 on Nasdaq. Pursuant to Part 3 of the Tel-Aviv Stock Exchange Regulations (Chapter A, Section B(1)), the Company’s common stock will not trade on the Tel-Aviv Stock Exchange on July 25, 2019.
A look at the shareholders of Pluristem Therapeutics Inc. (NASDAQ:PSTI) can tell us which group is most powerful...
The animal studies, conducted following guidance from the U.S. Food and Drug Administration (FDA) relating to its animal rule pathway, are designed to evaluate PLX-R18 as a potential prophylactic countermeasure against acute radiation syndrome (ARS) administered prior to radiation exposure. In addition to the DoD study, PLX-R18 is also being evaluated by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), as a treatment following radiation exposure.
Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today issued an update to its shareholders from its Chief Executive Officer, Yaky Yanay.
“I am proud and pleased in successfully completing the transition period and the appointment of Yaky as Pluristem’s sole CEO,” said Zami Aberman. “As Executive Chairman I will continue to take an active role in shaping Pluristem’s corporate development and business strategy as we are advancing towards completion of our phase III studies and targeting our marketing phase.
This serum-free media formulation was developed using Pluristem’s deep understanding in cell therapy industrial scale production standards, and the quality methods designed to support implementation in Phase III development and marketing. Achieving this significant technological challenge enables Pluristem large-scale, highly consistent production with operational independency from third-party suppliers for standard serum, an expensive and quantity limited product. PLX-R18 is the first product that Pluristem intends to manufacture using the serum-free media.
The pivotal study is also designed to measure long-term outcomes and collect parameters to assess the potential economic benefit of this kind of treatment. Additionally, an invited commentary that also appears in EJVES lends strong support for the study’s design and potential impact.
Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that it has filed a U.S. provisional patent application titled “Methods and Compositions for Producing Cannabinoids,” which covers the use of Pluristem’s state-of-the-art, proprietary 3-D cell culturing technology for the potential manufacturing of cannabinoid-producing cells.
Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced the Company has achieved a significant milestone in its ongoing development of PLX-PAD for the treatment of critical limb ischemia (CLI). The company has met its enrollment timelines relating to its Phase III pivotal study in CLI sooner than expected, and has successfully enrolled over 50% of the study’s patients, which allows for an interim analysis of efficacy after a one-year follow-up period under the European Medicine Agency’s (EMA) Adaptive Pathways pilot project, which PLX-PAD was selected for. The interim analysis, if positive, could support an application for conditional marketing approval, which could accelerate the approval and commercial availability of PLX-PAD in the Europe.
Anyone researching Pluristem Therapeutics Inc. (NASDAQ:PSTI) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory. Investors may think of vol...
Recent financing provides funding through multiple potentially value-creating milestonesProviding short and mid-term milestones, targeting marketing and significant contracts.
Pluristem Therapeutics Inc. (Nasdaq: PSTI, TASE: PLTR) (“Pluristem” or “Company”), a leading regenerative medicine company developing novel placenta-based cell therapy product candidates, announced today the pricing of an underwritten public offering of 27,142,858 shares of its common stock and warrants to purchase up to 27,142,858 shares of its common stock with an exercise price of $0.70 per share at a public offering price of $0.70 per share and accompanying warrant. The warrants in the underwritten public offering have a term of five years and are exercisable immediately upon issuance. Pluristem also announced the pricing of a concurrent registered direct offering of 1,428,571 shares of its common stock at a price of $0.70 per share.